[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 515,824
  • Shares Outstanding, K 16,570
  • Annual Sales, $ 102,480 K
  • Annual Income, $ -191,090 K
  • EBIT $ -120 M
  • EBITDA $ -116 M
  • 60-Month Beta 1.63
  • Price/Sales 5.12
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.54% (-3.13%)
  • Historical Volatility 75.82%
  • IV Percentile 19%
  • IV Rank 1.18%
  • IV High 1,186.13% on 11/04/25
  • IV Low 105.77% on 04/24/26
  • Expected Move (DTE 28) 1.34 (4.39%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 171
  • Open Int (30-Day) 692
  • Expected Range 29.28 to 31.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.92
  • Number of Estimates 7
  • High Estimate $-0.80
  • Low Estimate $-2.51
  • Prior Year $-1.40
  • Growth Rate Est. (year over year) -37.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.01 +2.03%
on 05/21/26
43.85 -30.17%
on 05/15/26
-3.73 (-10.86%)
since 04/21/26
3-Month
17.52 +74.77%
on 02/23/26
43.85 -30.17%
on 05/15/26
+12.20 (+66.23%)
since 02/20/26
52-Week
6.74 +354.57%
on 07/01/25
43.85 -30.17%
on 05/15/26
+22.24 (+265.26%)
since 05/21/25

Most Recent Stories

More News
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement...

STRO : 30.62 (-1.64%)
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful,...

STRO : 30.62 (-1.64%)
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

STRO : 30.62 (-1.64%)
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 47.39 (+0.47%)
STRO : 30.62 (-1.64%)
LZAGY : 63.6330 (+1.54%)
Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 30.62 (-1.64%)

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 34.33
2nd Resistance Point 33.35
1st Resistance Point 31.98
Last Price 30.62
1st Support Level 29.63
2nd Support Level 28.65
3rd Support Level 27.28

See More

52-Week High 43.85
Last Price 30.62
Fibonacci 61.8% 29.67
Fibonacci 50% 25.29
Fibonacci 38.2% 20.91
52-Week Low 6.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.